Individualized Therapy and Pharmacogenetic Test
Article Sidebar
Main Article Content
Abstract
Variability of drug response and toxic adverse effects are primarily responsible for the failure of drug therapy. Individual variation in genetic composition in regulating pharmacokinetic and pharmacodynamic processes, such as genes of drug metabolizing enzymes and genes of receptor or enzyme of drug response is critically important in determining drug efficacy. Pharmacogenetic testing will enable selection of appropriate drugs from the beginning, avoiding the drugs that could cause serious adverse events and assortment of alternative drugs to enhance therapeutic efficacy and minimize the illness.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, JangCG, et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005; 60: 418-422.
Bravo-Villalta HV, Yamamoto K, Nakamura K, BayaA, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol 2005; 61:179-184.
Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, et al. Preponderance of thiopurine S-methyltransferase deficiencyand heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol2001; 19: 2293-2301.
Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25:4057-4065.
Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, ChangCS, et al. Dihydropyrimidine dehydrogenasepharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 2004; 53:445-451.
Iacopetta B, Grieu F, Joseph D, Elsaleh H.A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85: 827-830.
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003; 138:819-830.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA1998; 279: 1200-1205.
Luo HR, Lu XM, Yao YG, Horie N, Takeishi K, JordeLB, et al. Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 2002; 40: 41-51.
Maekawa K, Saeki M, Saito Y, Ozawa S, Kurose K, Kaniwa N, et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J HumGenet 2007; 52: 804-819.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screeningfor hypersensitivity to abacavir. N Engl J Med2008; 358: 568-579.
Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6: 240-246.
Mattison LK, Fourie J, Desmond RA, Modak A, SaifMW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006; 12: 5491-5495.
Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relativeeffects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100:229-239.
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthasegene polymorphism predicts response tocapecitabine in advanced colorectal cancer. Int J Colorectal Dis 2002; 17: 46-49.
Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285-2293.
Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim BiophysActa 2006; 1766: 120-139.
Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-celllung cancer. J Clin Oncol 2007; 25: 587-595.
Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201-204.
Srimartpirom S, Tassaneeyakul W, Kukongviriyapan V. Thiopurine S-methyltransferase genetic polymorphism in the Thai population. Br J Clin Pharmacol 2004; 58: 66-70.
Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients inTaiwan. J Antimicrob Chemother 2007; 60:599-604.
Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003;73: 253-263.
Tanaka E. Gender-related differences in pharmaco-kinetics and their clinical significance. J Clin Pharm Ther 1999; 24: 339-346.
van Kuilenburg AB. Screening for dihydropyrimidinedehydrogenase deficiency: to do or not to do, that’s the question. Cancer Invest 2006; 24:215-217.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2testing in breast cancer. J Clin Oncol 2007;25: 118-145.
Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, KosugeT, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, andHER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98: 418-425.
Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R, Jr., et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007; 53:1199-1205.
Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45: 1-3.